Blocking these MAP kinase pathways with single agent inhibitors then prevented phosphorylation of ERK1/2 and cell proliferation, suggesting that IGFBP signaling promotes ovarian cancer growth through several cross-talking pathways [55]. The gene discussed is MAPK3; the disease is ovarian carcinoma.